Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million. With ...

On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement grants Lilly exclusive, worldwide rights to research, develop, ...

LUND, Sweden, June 26, 2021 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) announced today that the New Drug Application (NDA) by Camurus' US licensee Braeburn for Brixadi™ (buprenorphine) ...

Eli Lilly’s engineered peptide drugs Mounjaro and Zepbound are once-weekly injectable products, formulations that are expensive to manufacture and burdensome to patients who dislike needles. Lilly ...

Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty "We are pleased to enter into this collaboration with Lilly to bring ...

LUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* ...

Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic health. The collaboration and licence agreement gives Lilly exclusive global ...

CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findings A follow-up Phase 3 study will be discussed with regulatory authorities PLD is ...

LUND, Sweden, Nov. 10, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced positive topline results from a randomized, active-controlled Phase 1b study evaluating CAM2056, the company's ...

Camurus AB ( ($SE:CAMX) ) has provided an update. Camurus has announced an increase in its number of shares and votes following the exercise of ...